NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/11/26
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for EpilepsyZacks Investment Research • 06/02/26
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) MeetingBusiness Wire • 05/29/26
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy CareBusiness Wire • 05/29/26
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook RaisedZacks Investment Research • 05/13/26
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue GuidanceBusiness Wire • 05/12/26
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026Business Wire • 04/27/26
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/10/26
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 04/02/26
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?Zacks Investment Research • 04/02/26
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026Zacks Investment Research • 03/10/26
NeuroPace's Seizure ID and New Indication Could Expand RNS DemandZacks Investment Research • 03/10/26